Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY

Published 27/12/2023, 14:56
Updated 27/12/2023, 16:11
© Reuters.  US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday.

Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while the NASDAQ rose 0.17% to 15,099.84. The S&P 500 also rose, gaining, 0.07% to 4,777.93.

Check This Out: Over $2M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

Leading and Lagging Sectors

Consumer discretionary shares jumped by 0.5% on Wednesday.

In trading on Wednesday, financial shares fell by 0.2%.

Top Headline

Coherus BioSciences, Inc. (NASDAQ: CHRS) announced FDA approval of UDENYCA ONBODY for pegfilgrastim-cbqv.

Equities Trading UP

First Wave BioPharma, Inc. (NASDAQ: FWBI) shares shot up 236% to $12.35 after the company announced that it entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases.

Shares of Cingulate Inc. (NASDAQ: CING) got a boost, surging 122% to $4.65.

RiskOn International, Inc. (NASDAQ: ROI) shares were also up, gaining 76% to $0.25. RiskOn International expects to announce its new generative AI platform and technology partner on Jan. 3, 2024.

Equities Trading DOWN

Hallmark Financial Services, Inc. (NASDAQ: HALL) shares dropped 26% to $1.1597.

Hallmark Financial Services gave notice to Nasdaq of intention to voluntarily delist its shares of common stock from Nasdaq Global Market.

Shares of Baosheng Media Group Holdings Limited (NASDAQ: BAOS) were down 16% to $4.8999.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was down, falling 18% to $7.26 after the FDA placed a clinical hold on the IOV-LUN-202 trial in response to a recently reported Grade 5 adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Also Check This Out: Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Month

Commodities

In commodity news, oil traded down 0.6% to $75.13 while gold traded up 0.4% at $2,079.00.

Silver traded down 0.2% to $24.355 on Wednesday while copper rose 0.4% to $3.9185.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 rose 0.3%, London’s FTSE 100 rose 0.6% while Spain’s IBEX 35 Index rose 0.2% The German DAX rose 0.3% French CAC 40 rose 0.2%, while Italy’s FTSE MIB Index gained 0.3%.

Asia Pacific Markets

Asian markets closed higher on Wednesday, with Japan’s Nikkei 225 gaining 1.13%, Hong Kong’s Hang Seng Index rising 1.74% and China’s Shanghai Composite Index gaining 0.54%. India’s S&P BSE Sensex, meanwhile, rose 0.98%.

Japan's housing starts fell by 8.5% year-over-year in November following a 6.3% decline in the earlier month. Profits earned by Chinese industrial firms fell by 4.4% year-over-year to CNY 6,982.28 billion during the first eleven months of the year. Producer prices in Malaysia fell by 1.5% year-over-year in November.

Economics

The Richmond Fed's manufacturing index will be released at 10:00 a.m. ET.

Now Read This: Amazon, Adobe And 2 Other Stocks Insiders Are Selling

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.